MiR-137 and miR-197 induce apoptosis and suppress Tumorigenicity by targeting MCL-1 in multiple Myeloma

Clinical Cancer Research

Volumn 21, Issue 10, 2015, Pages 2399-2411

  Yang, Yijun ^a,d   Li, Fei ^b   Saha, Manujendra N ^a   Abdi, Jahangir ^a   Qiu, Lugui ^b   Chang, Hong ^a,c  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d Novade Pharmaceutical Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; MICRORNA; MICRORNA 137; MICRORNA 197; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN MCL 1; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; FIREFLY LUCIFERASE; MCL1 PROTEIN, HUMAN; MIRN137 MICRORNA, HUMAN; MIRN197 MICRORNA, HUMAN; RENILLA LUCIFERIN 2 MONOOXYGENASE;

3' UNTRANSLATED REGION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BAD GENE; BAX GENE; BID GENE; BIM GENE; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHROMOSOME 1P; COLONY FORMATION; GENE DELETION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA TRANSLATION; STOP CODON; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BINDING SITE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CARCINOGENESIS; CELL MOTION; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; HEK293 CELL LINE; METABOLISM; NUCLEOTIDE SEQUENCE; REPORTER GENE; RNA INTERFERENCE; SCID MOUSE; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS; BASE SEQUENCE; BINDING SITES; CARCINOGENESIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; GENETIC THERAPY; HEK293 CELLS; HUMANS; LUCIFERASES, FIREFLY; LUCIFERASES, RENILLA; MICE, SCID; MICRORNAS; MULTIPLE MYELOMA; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NEOPLASM TRANSPLANTATION; RNA INTERFERENCE;

EID: 84930381842     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1437     Document Type: Article

References (35)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351: 1860-73.
2. Barille-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG, et al. Advances in biology and therapy of multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2003:248-78.
3. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, et al. Treatment of multiple myeloma. Blood 2004;103:20-32.
4. Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet 2011;204:3-12.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
6. Barbarotto E, Carlin GA. Potential therapeutic applications of miRNAbased technology in hematological malignancies. Curr Pharm Des 2008;14:2040-50.
7. Calin GA, Croce CM. Investigation of microRNA alterations in leukemias and lymphomas. Methods Enzymol 2007;427:193-213.
8. Garzon R, Croce CM. MicroRNAs in normal and malignant hematopoiesis. Curr Opin Hematol 2008;15:352.
9. Zhou Y, Chen L, Barlogie B, Stephens O, WuX, Williams DR, et al. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci U S A 2010;107:7904-9.
10. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. HumanmicroRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101: 2999-3004.
11. Chang H, Qi X, Trieu Y, Xu W, Reader JC, Ning Y, et al. Multiple myeloma patients with CKS1B gene amplification have a shorter progression free survival post autologous transplantation. Br J Haematol. 2006;135:486-91.
12. Chang H, Ning Y, Qi X, Yeung J, Xu W. Chromosome 1p21 deletion is a novel prognostic factor in patients with multiple myeloma. Br J Haematol 2007;139:51-4.
13. Chang H, Qi X, Jiang A, Xu W, Trieu Y, Reece D. Chromosome 1p21 loss correlates with 1q21 gains and independently predicts an adverse clinical outcome in patients with multiple myeloma undergoing autologous stem cell transplantation. Bone Marrow Transplant 2010;45:117-21.
14. Marzin Y, Jamet D, Douet-Guilbert N, Morel F, LeBris MJ, Morice P, et al. Chromosome 1 abnormalities in multiple myeloma. Anticancer Res 2006;26:953-9.
15. Walker BA, Leone PE, Jenner MW, Li C, Gonzalez D, Johnson DC, et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 2006;108:1733-43.
16. Saha MN, Jiang H, Yang Y, Reece D, Chang H. PRIMA-1Met/APR-246 displays high antitumor activity in multiplemyeloma by induction of p73 and Noxa. Mol Cancer Ther 2013;12:2331-41.
17. Saha MN, Chen Y, Chen MH, Chen G, Chang H. Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents. Br J Cancer 2014;110:2224-31.
18. Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biol Ther 2010;9:936-44.
19. Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res 2004;32: D109-11.
20. Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011;19:116-22.
21. Amodio N, DiMartino MT, Foresta U, Leone E, Lionetti M, Leotta M, et al. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis 2012;3:e436.
22. DiMartino MT, Gulla A, Cantafio ME, Lionetti M, Leone E, Amodio N, et al. In vitro and in vivo anti-Tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget 2013;4:242-55.
23. Chng WJ, Gertz MA, Chung TH, Van Wier S, Keats JJ, Baker A, et al. Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma. Leukemia 2010;24:833-42.
24. Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L, et al. NCRI Haematology Oncology Studies Group. Mapping of chromosome 1p deletions inmyeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res 2011;17:7776-84.
25. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A 2008;105:12885-90.
26. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 2008;6:14.
27. Weber FTR, Broelsch CE, Frilling A, Eng C. A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab 2006;91:3584-91.
28. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008;93:1600-8.
29. Gutierrez NC, Sarasquete ME, Misiewicz-Krzeminska I, DelgadoM, De Las Rivas J, Ticona FV, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010;24:629-37.
30. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012; 18:6260-70.
31. Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005;19: 1248-52.
32. Nencioni A, Hua F, Dillon CP, Yokoo R, Scheiermann C, CardoneMH, et al. Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood 2005;105:3255-62.
33. Liu X, Chen X, Yu X, Tao Y, Bode AM, Dong Z, et al. Regulation of microRNAs by epigenetics and their interplay involved in cancer. J Exp Clin Cancer Res 2013;32:96.
34. Wong KY, Huang X, Chim CS. DNA methylation of microRNA genes in multiple myeloma. Carcinogenesis 2012;33:1629-38.
35. Chen X, Hu H, Guan X, Xiong G, Wang Y, Wang K, et al. CpG island methylation status ofmiRNAs in esophageal squamous cell carcinoma. Int J Cancer 2012;130:1607-13.